 SALT LAKE CITY, June 01, 2021 GLOBE NEWSWIRE -- On May 28, 2021, Myriad Genetics, Inc. NASDAQ: MYGN, a leader in genetic testing and precision medicine, completed the sale of its wholly-owned subsidiary, Myriad myPath, LLC, which owns the laboratory that offers the myPath Melanoma test, to Castle Biosciences, Inc for 32.5 million in cash. 